Sitagliptin plus chemo for advanced pancreatic cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests adding sitagliptin (a diabetes drug) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to see if the combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have pancreatic ductal adenocarcinoma that is locally advanced or has spread to other parts of the body (metastatic)
- You have not had chemotherapy for advanced disease, though prior treatment after surgery is okay if it ended more than 6 months ago
- You are generally able to care for yourself (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This study tests whether adding a diabetes treatment to standard chemotherapy helps people with pancreatic cancer that has spread and who also have diabetes. It might improve how well the cancer is controlled and how you feel.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial studies whether adding canagliflozin to standard chemotherapy (gemcitabine) can slow pancreatic cancer that cannot be fully removed by surgery. It may help some people control the cancer for longer and improve how well treatment works.
This trial tests a new combination of drugs (chiauranib, a PD-1 inhibitor, and two chemotherapy drugs) for people with a specific type of advanced pancreatic cancer who have not had prior treatment. It aims to see if this combination can help shrink tumors and improve outcomes.
Hear when a new PDAC - Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.